Last reviewed · How we verify
Colchicine Oral Product
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation.
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation. Used for Acute coronary syndrome or chronic coronary disease (post-myocardial infarction), Cardiovascular event reduction in patients with established coronary artery disease.
At a glance
| Generic name | Colchicine Oral Product |
|---|---|
| Sponsor | Ottawa Heart Institute Research Corporation |
| Drug class | Anti-inflammatory agent; microtubule inhibitor |
| Target | Tubulin (alpha and beta subunits) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Colchicine disrupts microtubule dynamics, which impairs the movement and function of neutrophils and other inflammatory cells. This reduces the inflammatory cascade and production of pro-inflammatory cytokines. In cardiovascular disease, this anti-inflammatory effect may reduce atherosclerotic plaque progression and recurrent cardiovascular events.
Approved indications
- Acute coronary syndrome or chronic coronary disease (post-myocardial infarction)
- Cardiovascular event reduction in patients with established coronary artery disease
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Myopathy
Key clinical trials
- Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk (PHASE3)
- Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease (EARLY_PHASE1)
- PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis (PHASE3)
- Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial (PHASE4)
- Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis (PHASE3)
- EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL (PHASE1, PHASE2)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- RegoNivo vs Standard of Care Chemotherapy in AGOC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Colchicine Oral Product CI brief — competitive landscape report
- Colchicine Oral Product updates RSS · CI watch RSS
- Ottawa Heart Institute Research Corporation portfolio CI